Last reviewed · How we verify

Antibiotic A 41030B (teicoplanin aglycone)

FDA-approved active Quality 10/100

Antibiotic A 41030B (generic name: teicoplanin aglycone) is a teicoplanin aglycone drug. It is currently FDA-approved.

Teicoplanin aglycone (Antibiotic A 41030B) is a marketed antibiotic that uniquely targets the enzyme Cathepsin L1, disrupting bacterial cell wall synthesis. Its key strength lies in its distinct mechanism of action, setting it apart from competitors such as boceprevir and telaprevir, which share a different target but are also patent-protected until 2027 and 2028, respectively. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameteicoplanin aglycone
Drug classteicoplanin aglycone
TargetCathepsin L1
Therapeutic areaMetabolic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Antibiotic A 41030B

What is Antibiotic A 41030B?

Antibiotic A 41030B (teicoplanin aglycone) is a teicoplanin aglycone drug.

What is the generic name of Antibiotic A 41030B?

teicoplanin aglycone is the generic (nonproprietary) name of Antibiotic A 41030B.

What drug class is Antibiotic A 41030B in?

Antibiotic A 41030B belongs to the teicoplanin aglycone class. See all teicoplanin aglycone drugs at /class/teicoplanin-aglycone.

What development phase is Antibiotic A 41030B in?

Antibiotic A 41030B is FDA-approved (marketed).

What does Antibiotic A 41030B target?

Antibiotic A 41030B targets Cathepsin L1 and is a teicoplanin aglycone.

Related